





### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

: Arindam Datta et al.

Confirmation No.: 7724

Serial No.

10/059,637

Art Unit: 3731

Filed

: January 29, 2002

Examiner: Uyen T. Ho

For

Biodegradable Stent

Attention: Examiner Uyen T. Ho

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

# CORRECTION TO SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT TRANSMITTED VIA FACSIMILE ON SEPTEMBER 28, 2005

Dear Sir:

As a follow-up to our telephone conversation on Friday, October 7, 2005 in regards to the above-mentioned case, as I explained, on September 28, 2005, a Second Supplemental Information Disclosure and the Form 1449 was faxed to the USPTO. The Form 1449 was the incorrect copy. As you have requested, attached please find the correct Form 1449 and the Transmittal.

The Commissioner is hereby authorized to charge Johnson & Johnson Deposit Account No. 10-0750/ETH1635/MSG any additional fees that may be required. This sheet is submitted in triplicate.

Respectfully submitted,

/Ceceile Solomon/

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-2816

Docket No. ETH1635

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Arindam Datta et al. Confirmation No.: 7724

Serial No.: 10/059,637 Art Unit: 3731

Filed : January 29, 2002 Examiner: Uyen T. Ho

For : Biodegradable Stent

> I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

October 7, 2005 (Date of Deposit) Matthew S. Goodwin (Name of applicant, assignee, or Registered Representative) /Matthew S. Goodwin/ (Signature) October 7, 2005 (Date of Signature)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

### SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the Information Disclosure Statement mailed on November 17, 2004.

Pursuant to 37 C.F.R. \$1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the aboveidentified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. \$1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this

10/12/2005 MBERHE 00000057 100750 10059637 180.00 DA

01 FC:1806

information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

$\square$ In accordance with §1.97(b), since this Information
Disclosure Statement is being filed either within three months
of the filing date of the above-identified national application
(other than a continued prosecution application under
$\S1.53(d)$ ), within three months of the date of entry into the
national stage of the above identified application as set forth
in $\S$ 1.491, or before the mailing date of a first Office Action
on the merits of the above-identified application, or before
the mailing date of a first Office Action after the filing of a
request for continued examination under $\S 1.114$ , no additional
fee is required.
$\square$ In accordance with §1.129(a), this Information
Disclosure Statement is being filed in connection with $\Box$ the
first or   second After Final Submission, therefore:
Statement in Accordance with §1.97(e)
(attached); or
☐ Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth
in <b>§</b> 1.17(p).
$\square$ In accordance with §1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in $\S 1.97$ (b) above but before the mailing date of either a Final

Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of: П Statement in Accordance with §1.97(e) (attached); or Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in  $\S1.17(p)$ .  $\boxtimes$ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with \$1.97(e) as set forth below and the fee of \$180.00 as set forth in \$1.17(p). Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith. Copies of only foreign patent documents and nonpatent literature are enclosed in accordance with 37 CFR 1.98 (a)(2). (The U.S. patents and each U.S. patent application publication listed on the attached Form PTO-1449 are not enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i).  $\boxtimes$ There are no listed references which are not in the

English language.

The relevance of those listed references whice	n are
not in the English language is as follows:	
Attached are copies of search report(s) from	
corresponding patent application(s), which are listed or	n the
attached Submission Under MPEP 609 D.	
Copies of the references listed on the search	
report(s) are included except for those previously cite	d.
,	
☐ Attached are the following non-published pend	ing
patent applications which may be deemed relevant, which	are
listed on the attached Submission Under MPEP 609 D.	
Please charge any deficiency or credit any overpay	ment to
Deposit Account No. 10-0750/ETH1635/WKW. This form is	
submitted in triplicate.	
Respectfully submitted,	
/Matthew S. Goodwin/	
Matthew S. Goodwin	
Reg. No. 32,839	
Attorney for Applicants	

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-3849 DATED: October 7, 2005 O(PE 0CT 1 1 2005

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

a conceder of information unless it displays	a valid Civid Colludi Hullidel.
Confirmation Number	7724
Application Number	10/059,637
Filing Date	01/29/2002
First Named Inventor	Arindam Datta
Group Art Unit	3731
Examiner Name	Uyen T. Ho
Attorney Docket Number	ETH-1635

#### **U.S. PATENT DOCUMENTS**

		U.S. Patent Docu	ment			
Examiner Cite Initials No.1 Number		Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		6,338,739 B1	Α	Datta et al.	01 15 2002	
		6,573,312 B1	Α	Datta et al	03-25 2003	
		6,423,092 B1,	Α	Datta et al	06-16-1998	
		5,769,883	Α			
		5,957,975		Lafont et al.	09/29/1999	
		6,267,776		O'Connell	07/31/2001	
		5,766,710		Turnlund et al.	06/16/1998	
		5,500,013		Buscemi et al.	03/19/1996	

### **FOREIGN PATENT DOCUMENTS**

		Foreign	Foreign Patent Document		Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials	Cite No. <sup>1</sup>	Office <sup>3</sup>	Number⁴ Kii	ndCode⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	Τ <sup>6</sup>
		wo	98/56312	A1	Scimed Life Systems, Inc.	04-03-1991		
		wo	9934750	Α	Bioamide, Inc.	07-15-1999		
		wo	0 604 022	A	Advanced Cardiovascular Systems, Inc	06-27-2001		
		EP	1 112 724	Α	Ethicon, Inc.	03-17-2004		
		EP	0 420 541	A2	Bristol-Myers Squibb Company	09/24/1990		
		EP	0 923 912	A2	Schneider Inc.	06/26/1998		
		EP	1 110 561	A1	Ethicon, Inc.	12/21/200		
				]				

Examiner	Date	
Signature	Considered	
Oignature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.



### SUBMISSION UNDER MPEP 609 D

Application Number	10/059,637
Filing Date	01/29/2002
First Named Inventor	Arindam Datta
Group Art Unit	3731
Examiner Name	Uyen T. Ho
Attorney Docket Number	ETH-1635

Page 1 of 1

		1 490 1 01 1				
U.S. PATENT DOCUMENTS						
		No. of Botonia and April 2	U.S. Patent Docum	nent	Pages Columns Lines	
Examiner Initials	Cite No. <sup>1</sup>	Name of Patentee or Applicant of Cited Document	Number	Kind Code <sup>2</sup> (if known)	Pages, Columns, Lines, where relevant passages or relevant figures appear	
	_					
		,				

## **FOREIGN PATENT DOCUMENTS** Foreign Patent Document Pages, Columns, Lines, Name of Patentee or where relevant passages Examiner Initials Cite or relevant figures **Applicant of Cited Document** Office<sup>3</sup> Number⁴ KindCode5 appear No.1 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), Cite No.<sup>1</sup> Examiner title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published Initials\* Search Report EP 00 31 1543, dated 06/12/02 Search Report EP 04 25 3754, dated 08/11/04

Examiner	Date	· · · · · · · · · · · · · · · · · · ·
Signature	Considered	
	<del></del>	·